Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang Liang

Showing results (271-280 of 293) with videos related to

Pageof 30
Sort By:
NPJ Primary Care Respiratory Medicine|June 4, 2021
A predictive score for progression of COVID-19 in hospitalized persons: a cohort studyJingbo Xu, Weida Wang, Honghui Ye, et al.
Iscience|January 8, 2024
Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphomaChen Jiang, Li-Yun Huang, Ji-Hao Zhou, et al.
Therapeutic Advances in Hematology|February 24, 2025
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging studyChunkang Chang, Takahiro Suzuki, Yang Liang, et al.
Blood Science (Baltimore, Md.)|June 24, 2024
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry studyMingyuan Sun, Qingsong Yin, Yang Liang, et al.
Leukemia|February 20, 2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphomaZegeng Chen, He Huang, Huageng Huang, et al.
Cancer Communications (London, England)|October 26, 2021
DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemiaHao Zhang, Nuo Cheng, Zhihui Li, et al.
Journal of Hematology & Oncology|August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology|February 21, 2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Medical Virology|April 21, 2025
A Visual Nomogram Survival Prediction Model in Acquired Immune Deficiency Syndrome (AIDS)-Related Diffuse Large B-Cell LymphomaTao Yang, Haike Lei, Jun Li, et al.
Journal of Hematology & Oncology|November 1, 2022
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Pageof 30

Showing results (271-280 of 293) with videos related to

Sort By:
Pageof 30
NPJ Primary Care Respiratory Medicine|June 4, 2021
A predictive score for progression of COVID-19 in hospitalized persons: a cohort studyJingbo Xu, Weida Wang, Honghui Ye, et al.
Iscience|January 8, 2024
Epstein-Barr virus-based prognostic model in nodular sclerosis classic Hodgkin lymphomaChen Jiang, Li-Yun Huang, Ji-Hao Zhou, et al.
Therapeutic Advances in Hematology|February 24, 2025
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging studyChunkang Chang, Takahiro Suzuki, Yang Liang, et al.
Blood Science (Baltimore, Md.)|June 24, 2024
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry studyMingyuan Sun, Qingsong Yin, Yang Liang, et al.
Leukemia|February 20, 2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphomaZegeng Chen, He Huang, Huageng Huang, et al.
Cancer Communications (London, England)|October 26, 2021
DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemiaHao Zhang, Nuo Cheng, Zhihui Li, et al.
Journal of Hematology & Oncology|August 18, 2022
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Hematology & Oncology|February 21, 2023
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Journal of Medical Virology|April 21, 2025
A Visual Nomogram Survival Prediction Model in Acquired Immune Deficiency Syndrome (AIDS)-Related Diffuse Large B-Cell LymphomaTao Yang, Haike Lei, Jun Li, et al.
Journal of Hematology & Oncology|November 1, 2022
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialQian Jiang, Zongru Li, Yazhen Qin, et al.
Pageof 30